EE200000171A - Uued NPY antagonistid - Google Patents

Uued NPY antagonistid

Info

Publication number: EE200000171A
Authority: EE; Estonia
Prior art keywords: npy antagonists; new; new npy; antagonists; npy
Prior art date: 1997-09-23

Application number

EEP200000171A

Other languages

English (en)

Inventor

Bergman Nils-�ke

D'ambra Thomas

Pilling Garry

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-23

Filing date

1998-09-21

Publication date

2001-04-16

1998-09-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-04-16 Publication of EE200000171A publication Critical patent/EE200000171A/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EEP200000171A 1997-09-23 1998-09-21 Uued NPY antagonistid EE200000171A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9703414A SE9703414D0 (sv)	1997-09-23	1997-09-23	New compounds
PCT/SE1998/001686 WO1999015498A1 (en)	1997-09-23	1998-09-21	New npy antagonists

Publications (1)

Publication Number	Publication Date
EE200000171A true EE200000171A (et)	2001-04-16

Family

ID=20408331

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200000171A EE200000171A (et)	1997-09-23	1998-09-21	Uued NPY antagonistid

Country Status (21)

Country	Link
US (1)	US6127414A (et)
EP (1)	EP1017672B1 (et)
JP (1)	JP2001517651A (et)
KR (1)	KR20010024220A (et)
CN (1)	CN1279666A (et)
AR (1)	AR017138A1 (et)
AT (1)	ATE228500T1 (et)
AU (1)	AU9288998A (et)
BR (1)	BR9812492A (et)
CA (1)	CA2303528A1 (et)
DE (1)	DE69809782T2 (et)
EE (1)	EE200000171A (et)
IL (1)	IL134993A0 (et)
IS (1)	IS5410A (et)
NO (1)	NO20001483L (et)
PL (1)	PL339617A1 (et)
SE (1)	SE9703414D0 (et)
SK (1)	SK3602000A3 (et)
TR (1)	TR200000785T2 (et)
WO (1)	WO1999015498A1 (et)
ZA (1)	ZA988353B (et)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9802075D0 (sv) *	1998-06-11	1998-06-11	Astra Ab	New use
US6312898B1 (en) *	1999-04-15	2001-11-06	Hormos Medical Oy, Ltd.	Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
SE9902596D0 (sv) *	1999-07-06	1999-07-06	Astra Ab	Pharmaceutically active compounds
EP1095933A1 (en)	1999-10-30	2001-05-02	Aventis Pharma Deutschland GmbH	Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
SE0101328D0 (sv) *	2001-04-12	2001-04-12	Astrazeneca Ab	Therapeutic treatment
JP4010951B2 (ja) *	2001-05-15	2007-11-21	大正製薬株式会社	アルギニン誘導体
WO2004098591A2 (en)	2003-05-05	2004-11-18	Probiodrug Ag	Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP1680120A2 (en)	2003-11-03	2006-07-19	Probiodrug AG	Combinations useful for the treatment of neuronal disorders
FR2864830B1 (fr) *	2004-01-06	2006-03-10	Centre Nat Rech Scient	Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
EP1713780B1 (en)	2004-02-05	2012-01-18	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
FR2884516B1 (fr) *	2005-04-15	2007-06-22	Cerep Sa	Antagonistes npy, preparation et utilisations
KR100689499B1 (ko) *	2005-10-26	2007-03-02	삼성전자주식회사	휴대단말기에서 키 설정 정보 디스플레이 방법
WO2007064272A1 (en) *	2005-11-29	2007-06-07	Astrazeneca Ab	Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (en)	2006-11-30	2012-04-18	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
EP2117540A1 (en)	2007-03-01	2009-11-18	Probiodrug AG	New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
WO2011029920A1 (en)	2009-09-11	2011-03-17	Probiodrug Ag	Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
ES2481823T3 (es)	2010-03-10	2014-07-31	Probiodrug Ag	Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
ES2570167T3 (es)	2011-03-16	2016-05-17	Probiodrug Ag	Derivados de benzimidazol como inhibidores de glutaminil ciclasa
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase
KR20250120302A (ko) *	2022-11-23	2025-08-08	라디오네틱스 온콜로지, 인코포레이티드	뉴로펩티드 y1 수용체(npy1r) 표적화 치료제 및 이의 용도
WO2025144920A1 (en) *	2023-12-28	2025-07-03	Radionetics Oncology, Inc.	Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5873821A (en) *	1992-05-18	1999-02-23	Non-Invasive Technology, Inc.	Lateralization spectrophotometer
DE4326465A1 (de) *	1993-01-20	1995-02-09	Thomae Gmbh Dr K	Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544686A1 (de) *	1995-11-30	1997-06-05	Thomae Gmbh Dr K	Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) *	1995-11-30	1997-06-05	Thomae Gmbh Dr K	Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2000501107A (ja) *	1996-01-09	2000-02-02	イーライ・リリー・アンド・カンパニー	ベンズイミダゾリル神経ペプチドｙ受容体アンタゴニスト
CA2249222C (en) *	1996-03-21	2005-11-08	Banyu Pharmaceutical Co., Ltd.	Aminopyridine derivatives
EP1007073A4 (en) *	1996-06-04	2002-03-27	Synaptic Pharma Corp	METHODS OF MODIFYING FOOD BEHAVIOR, COMPOUNDS USEFUL IN SAID METHODS, AND DNA ENCODING A HYPOTHALAMIC NEUROPEPTIDE Y / PEPTIDE YY Y5 RECEPTOR
CA2260982A1 (en) *	1996-07-23	1998-01-29	Neurogen Corporation	Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
ATE230403T1 (de) *	1996-07-23	2003-01-15	Neurogen Corp	Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande
PT918761E (pt) *	1996-07-23	2003-09-30	Neurogen Corp	Algumas amidas e aminas substituidas com derivados de benzilamina uma nova classe de ligandos especificos do neuropeptido y1
DK0984778T3 (da) *	1996-08-23	2002-09-16	Agouron Pharma	Neuropeptid-Y-ligander
DE69720051T2 (de) *	1996-12-03	2003-09-04	Banyu Pharmaceutical Co., Ltd.	Harnstoffderivate
AU5410498A (en) *	1996-12-12	1998-07-03	Banyu Pharmaceutical Co., Ltd.	Pyrazole derivatives
WO1998025908A1 (en) *	1996-12-13	1998-06-18	Banyu Pharmaceutical Co., Ltd.	Novel aminopyrazole derivatives
DE69729315T2 (de) *	1996-12-16	2005-06-23	Banyu Pharmaceutical Co., Ltd.	Aminopyrazolderivate
WO1998033791A1 (en) *	1997-02-04	1998-08-06	Bristol-Myers Squibb Company	Dihydropyrimidone derivatives as npy antagonists
WO1998035944A1 (en) *	1997-02-14	1998-08-20	Bayer Corporation	Amides as npy5 receptor antagonists
JP2002241368A (ja) *	1997-02-18	2002-08-28	Shionogi & Co Ltd	新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998040356A1 (en) *	1997-03-12	1998-09-17	Banyu Pharmaceutical Co., Ltd.	Drugs containing aminopyridine derivatives as the active ingredient
US5889016A (en) *	1997-06-26	1999-03-30	Bristol-Myers Squibb Company	Dihydropyrimidone derivatives as NPY antagonists

1997
- 1997-09-23 SE SE9703414A patent/SE9703414D0/xx unknown
1998
- 1998-09-11 ZA ZA988353A patent/ZA988353B/xx unknown
- 1998-09-21 CA CA002303528A patent/CA2303528A1/en not_active Abandoned
- 1998-09-21 EP EP98945708A patent/EP1017672B1/en not_active Expired - Lifetime
- 1998-09-21 AT AT98945708T patent/ATE228500T1/de not_active IP Right Cessation
- 1998-09-21 JP JP2000512808A patent/JP2001517651A/ja active Pending
- 1998-09-21 AU AU92889/98A patent/AU9288998A/en not_active Abandoned
- 1998-09-21 SK SK360-2000A patent/SK3602000A3/sk unknown
- 1998-09-21 IL IL13499398A patent/IL134993A0/xx unknown
- 1998-09-21 DE DE69809782T patent/DE69809782T2/de not_active Expired - Fee Related
- 1998-09-21 WO PCT/SE1998/001686 patent/WO1999015498A1/en not_active Ceased
- 1998-09-21 PL PL98339617A patent/PL339617A1/xx unknown
- 1998-09-21 CN CN98811336A patent/CN1279666A/zh active Pending
- 1998-09-21 US US09/171,779 patent/US6127414A/en not_active Expired - Fee Related
- 1998-09-21 TR TR2000/00785T patent/TR200000785T2/xx unknown
- 1998-09-21 KR KR1020007003029A patent/KR20010024220A/ko not_active Withdrawn
- 1998-09-21 BR BR9812492-7A patent/BR9812492A/pt not_active IP Right Cessation
- 1998-09-21 EE EEP200000171A patent/EE200000171A/et unknown
- 1998-09-22 AR ARP980104740A patent/AR017138A1/es unknown
2000
- 2000-03-20 IS IS5410A patent/IS5410A/is unknown
- 2000-03-22 NO NO20001483A patent/NO20001483L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
SE9703414D0 (sv)	1997-09-23
ZA988353B (en)	1999-03-23
BR9812492A (pt)	2000-09-26
TR200000785T2 (tr)	2000-09-21
IL134993A0 (en)	2001-05-20
NO20001483D0 (no)	2000-03-22
CN1279666A (zh)	2001-01-10
DE69809782D1 (de)	2003-01-09
JP2001517651A (ja)	2001-10-09
EP1017672A1 (en)	2000-07-12
ATE228500T1 (de)	2002-12-15
AU9288998A (en)	1999-04-12
SK3602000A3 (en)	2001-01-18
WO1999015498A1 (en)	1999-04-01
DE69809782T2 (de)	2003-07-17
EP1017672B1 (en)	2002-11-27
US6127414A (en)	2000-10-03
PL339617A1 (en)	2001-01-02
CA2303528A1 (en)	1999-04-01
NO20001483L (no)	2000-05-23
AR017138A1 (es)	2001-08-22
IS5410A (is)	2000-03-20
KR20010024220A (ko)	2001-03-26

Publication	Publication Date	Title
EP0986385A4 (en)	2001-05-16	GONADORELIN ANTAGONISTS
EE200000171A (et)	2001-04-16	Uued NPY antagonistid
ATE233260T1 (de)	2003-03-15	Muscarin-antagonisten
DK0973746T3 (da)	2004-02-02	Substituerede 3-cyanoquinoliner
MX209959B (es)	2002-08-26	4-(3-heterociclil-1-benzoil)pirazoles
ID23168A (id)	2000-03-23	Reseptor anatagonis vitronektin
DK1137493T3 (da)	2004-07-26	Forkompressionssystem
NO20000542L (no)	2000-04-04	Endothelin-antagonister
PT1036083E (pt)	2004-10-29	Novos 9a-azalidos
DE69818447D1 (de)	2003-10-30	Verbesserungen bezüglich der bilderzeugung
DE59813487D1 (de)	2006-05-24	Substituierte 4-benzoyl-pyrazole
NO20002555D0 (no)	2000-05-18	Skjøt
PT964867E (pt)	2005-07-29	Antagonistas da taquicinima
DK0983266T3 (da)	2002-03-11	Hidtil ukendte tetrahydrosioquinolinthiophencarboximidamider
NO305410B1 (no)	1999-05-25	B°lgekraftverk
DE59710430D1 (de)	2003-08-14	Substituierte 4-benzoyl-pyrazole
DE59807877D1 (de)	2003-05-15	Substituierte 4-benzoyl-pyrazole
ID24079A (id)	2000-07-06	Aminoheteroksiklilamida tersubstitusi
DE59810960D1 (de)	2004-04-15	Substituierte phenyluracile
DE69708044D1 (de)	2001-12-13	Konstruktionsteil
KR980001295U (ko)	1998-03-30	개량 도장
ATE266645T1 (de)	2004-05-15	Substituierte phenyluracile
SE9704399D0 (sv)	1997-11-28	New combination
SK2042U (sk)	1998-12-02	Balkón
NO975448L (no)	1999-05-27	L°fteverkt°y